<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01831076</url>
  </required_header>
  <id_info>
    <org_study_id>01-0627.cc</org_study_id>
    <nct_id>NCT01831076</nct_id>
  </id_info>
  <brief_title>Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors</brief_title>
  <official_title>Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors. A Phase II Study to Identify Molecular Predictors for Hormone Responsiveness and/or Resistance.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well exemestane before surgery works in treating
      postmenopausal patients with newly diagnosed estrogen receptor positive stage II-III breast
      cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using
      exemestane may fight breast cancer by blocking the use of estrogen by the tumor cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will develop preliminary data regarding the efficacy and safety of exemestane in
      the preoperative treatment of postmenopausal women with ER+ or PR+ tumors. This trial is also
      designed to develop a predictive model to correlate expression of the known isoforms of ER
      and progesterone receptor (PR) and the aromatase enzyme with response to estrogenic
      deprivation using exemestane.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2002</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate as Measured by Clinical Exam, Standard Imaging, and Surgical Pathology Findings</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Evaluated using chi-square analysis.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage III Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (exemestane, surgery)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive exemestane orally daily for 4 months in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment (exemestane, tamoxifen, surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive exemestane plus tamoxifen orally daily for 4 months in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (exemestane, surgery)</arm_group_label>
    <other_name>107868-30-4,</other_name>
    <other_name>6-Methyleneandrosta-1,</other_name>
    <other_name>4-diene-3,17-dione,</other_name>
    <other_name>713563,</other_name>
    <other_name>Aromasin,</other_name>
    <other_name>FCE 24304,</other_name>
    <other_name>FCE-24304,</other_name>
    <other_name>PNU 155971</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane and tamoxifen</intervention_name>
    <description>exemestane 25 mg po daily and tamoxifen 20 mg po daily given concurrently for 4 months prior to surgery</description>
    <arm_group_label>treatment (exemestane, tamoxifen, surgery)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed breast cancer

          -  ER positive (+)

          -  Primary tumor 2-4 regional lymph nodes 0-2 (T2-4N0-2); patients may have metastatic
             disease, provided local-regional surgery is clinically indicated

          -  Clinical stage II/III

          -  Postmenopausal- defined as having had a previous bilateral oophorectomy or, for women
             with no prior hysterectomy, the absence of spontaneous menstrual cycles for more than
             1 year

          -  Newly diagnosed

          -  Patients with prior non-breast malignancies are eligible if they have been disease
             free for &gt;= 5 years before study entry; patients with squamous or basal cell carcinoma
             of the skin that has been effectively treated, carcinoma in situ of the cervix that
             has been treated by surgery only, or lobular carcinoma in situ (LCIS) of the
             ipsilateral or contralateral breast that has been treated by surgery only are
             eligible, even if the cancer was diagnosed within 5 years before randomization

          -  Serum creatinine =&lt; 1.5 x institutional upper limit of normal (ULN)

          -  Hemoglobin within normal limits for institution

          -  Absolute granulocyte count &gt;= 1500

          -  Platelet count &gt;= 100,000

          -  Serum glutamic oxaloacetic transaminase (SGOT), aspartate aminotransferase (AST) or
             serum glutamate pyruvate transaminase (SGPT), alanine aminotransferase (ALT) =&lt; 2.5 x
             ULN

          -  Total bilirubin &lt; 2 x ULN for institution

          -  Alkaline phosphatase &lt; 2 x the ULN

        Exclusion Criteria:

          -  Completely resected

          -  Prior hormone or chemotherapy

          -  Unable to take oral medication

          -  Patients who have nonmalignant systemic disease (cardiovascular, renal, hepatic, etc.)
             that would preclude their being subjected to protocol therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Elias, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 4, 2013</study_first_submitted>
  <study_first_submitted_qc>April 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2013</study_first_posted>
  <results_first_submitted>October 26, 2018</results_first_submitted>
  <results_first_submitted_qc>October 26, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 23, 2018</results_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>estrogen receptor-positive breast cancer</keyword>
  <keyword>progesterone receptor-positive breast cancer</keyword>
  <keyword>Postmenopausal</keyword>
  <keyword>Exemestane</keyword>
  <keyword>Tamoxifen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Exemestane</title>
          <description>Patients receive exemestane orally daily for 4 months in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
Exemestane: Given PO</description>
        </group>
        <group group_id="P2">
          <title>Exemestane Plus Tamoxifen</title>
          <description>preoperative exemestane plus concurrent tamoxifen for 4 months, then surgery. Patients with &gt;T2 ER+ Her2- BC.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Exemestane</title>
          <description>Patients receive exemestane orally daily for 4 months in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
Exemestane: Given PO</description>
        </group>
        <group group_id="B2">
          <title>Exemestane Plus Tamoxifen</title>
          <description>preoperative exemestane plus concurrent tamoxifen for 4 months, then surgery. Patients with &gt;T2 ER+ Her2- BC.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate as Measured by Clinical Exam, Standard Imaging, and Surgical Pathology Findings</title>
        <description>Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Evaluated using chi-square analysis.</description>
        <time_frame>Up to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exemestane</title>
            <description>Patients receive exemestane orally daily for 4 months in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
Exemestane: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Exemestane Plus Tamoxifen</title>
            <description>preoperative exemestane plus concurrent tamoxifen for 4 months, then surgery. Patients with &gt;T2 ER+ Her2- BC.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate as Measured by Clinical Exam, Standard Imaging, and Surgical Pathology Findings</title>
          <description>Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Evaluated using chi-square analysis.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Consent to surgery (approximately four months)</time_frame>
      <desc>Adverse event collection and reporting not required by protocol. Only SAE reporting required.</desc>
      <group_list>
        <group group_id="E1">
          <title>Exemestane</title>
          <description>Patients receive exemestane orally daily for 4 months in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
Exemestane: Given PO</description>
        </group>
        <group group_id="E2">
          <title>Exemestane Plus Tamoxifen</title>
          <description>preoperative exemestane plus concurrent tamoxifen for 4 months, then surgery. Patients with &gt;T2 ER+ Her2- BC.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anthony Elias</name_or_title>
      <organization>University of Colorado</organization>
      <phone>720-848-0347</phone>
      <email>anthony.elias@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

